Wikidata

(Q43250046)

English

KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial

scientific article published on 2 November 2009

In more languages

Statements

title
KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial (English)
1 reference
stated in
Europe PubMed Central
PubMed ID
19884549
retrieved
17 November 2017
author name string
Matthew T Seymour
series ordinal
2
1 reference
stated in
Europe PubMed Central
PubMed ID
19884549
retrieved
17 November 2017
Philip Chambers
series ordinal
3
1 reference
stated in
Europe PubMed Central
PubMed ID
19884549
retrieved
17 November 2017
Faye Elliott
series ordinal
4
1 reference
stated in
Europe PubMed Central
PubMed ID
19884549
retrieved
17 November 2017
Catherine L Daly
series ordinal
5
1 reference
stated in
Europe PubMed Central
PubMed ID
19884549
retrieved
17 November 2017
Angela M Meade
series ordinal
6
1 reference
stated in
Europe PubMed Central
PubMed ID
19884549
retrieved
17 November 2017
Graham Taylor
series ordinal
7
1 reference
stated in
Europe PubMed Central
PubMed ID
19884549
retrieved
17 November 2017
publication date
2 November 2009
1 reference
stated in
Europe PubMed Central
PubMed ID
19884549
retrieved
17 November 2017
page(s)
5931-5937
1 reference
stated in
Europe PubMed Central
PubMed ID
19884549
retrieved
17 November 2017

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q43250046&oldid=1984861309"